Baxter's Turnaround Raise Comes With a 2027 Asterisk

A $50 million cephalosporin exit, a new CFO who won't quantify next year, and a stock up 12% in 90 days while still 75% below its peak.

BAX · Earnings Call · 2026-10-29

A raise with an asterisk

Baxter delivered the quarter its turnaround needed: roughly $3 billion in sales, up 5% organic, adjusted EPS of $0.58, free cash flow of $448 million and $705 million year-to-date. Management raised full-year organic growth to 3–4% from 2–3% and lifted the low end of EPS guidance to $2.05–$2.15. On the surface, a clean beat-and-raise. But the call's most consequential decision was a subtraction. Baxter will stop making cephalosporin products at its Round Lake, Illinois facility, a move that removes about $50 million of 2026 sales and $30 million of operating income. Andrew Hider framed it as simplification and a partial answer to the warning letter: “by repositioning the facility exclusively for non-ceph production, we will simplify and streamline our operations while supporting supply continuity of the non-ceph portfolio.” — Andrew Hider, Chief Executive Officer · 2026-10-29 That is the right operational call — Round Lake's complexity has been a recurring quality and supply problem — but it is also an admission that the fix costs money and time. The discontinue production of cephalosporin products decision is now one of the company's freshest high-momentum themes, alongside supply challenge and inflationary pressure.

The 2027 wall

John Rogers, three weeks into the CFO job, spent his first call constructing a wall around 2027. He listed the headwinds with unusual candor: TSA services related to Vantive end by January 2027; tariffs will not repeat the 2026 refund benefit; inflation steps up due to cap-and-roll and inventory flow-through; ceph disappears; product exits in Front Line Care continue. He then declined to size the net.

I'm 3 weeks into the role. Obviously, I understand why there's going to be a lot of focus on 2027 right now. But I'm going to need a little bit of time just to thoroughly evaluate all these different moving dynamics.
John Rogers, Chief Financial Officer · 2026-10-29

That is prudent for a new CFO. It is also a sharp contrast with April, when Hider told investors “we would expect to have modest growth within 2027” — Andrew Hider, Chief Executive Officer · 2026-04-30. The company has since added a ceph exit and a more explicit inflation warning. The April comment now looks like a marker the company may not clear. Rogers' only qualitative hedge was that there are “clearly some margin headwinds, there are also some margin tailwinds” — John Rogers, Chief Financial Officer · 2026-10-29 — a sentence that says nothing about magnitude. The margin math is unforgiving. Gross margin was 34.9% in the latest reported quarter, down 0.4pp year over year, and the Q3 call showed why: mix shifted toward lower-margin Drug Compounding, which grew 9%, and away from injectables, which fell 3%, while pricing contributed less because 2025 benefited from two GPO renewals. Revenue of $3.0 billion was up 5% year over year but still 33% below the 2015 peak. The cost side is the only lever with visible traction: cost actions and Baxter GPS produced more than 700 continuous-improvement events year-to-date, with roughly 200 in flight and 350 more planned.

What stopped being said

The most telling absence is Novum LVP. For five straight quarters, the infusion pump crisis dominated the keyword list — Novum LVP was a top-five theme in 2025Q3 and still a top-30 theme in 2026Q2, but it has now fallen out of the top 30 entirely. On this call, Hider mentioned it only when an analyst asked about pump milestones: “We're continuing to make good progress with Novum LVP. And we're working closely with the regulatory authorities in this process.” — Andrew Hider, Chief Executive Officer · 2026-10-29 No timeline, no filing update, no quantification. A year ago, Heather Knight was telling investors “we remain confident in the Novum platform” — Heather Knight, Executive Vice President and Chief Operating Officer · 2025-07-31; two quarters ago, Hider said “we're making progress” — Andrew Hider, CEO · 2026-07-30. The language has not evolved — which is itself the signal. The pump issue has not been solved; it has been deprioritized in the narrative because the company now has a different story to tell. The same is true of contract manufacturer supply problems in injectables. Management says the impact is improving but still refuses to size it, even when asked directly whether it could offset the ceph exit. The answer was that Baxter is 'not outlining that in totality.' That is a small red flag for 2027 modeling.

The tape is pricing cash, not growth

The stock is up 11.7% over the last 90 trading days, yet it remains 75% below its 2020 peak and carries a $12.1 billion market cap. The market is not paying for the 5% organic growth; it is paying for the deleveraging and cash-flow inflection. Free cash flow was $252 million in the latest filed quarter, up 38% year over year, and the company completed a $600 million tender offer, retiring $864 million of debt. At 9.1x free cash flow, the valuation still embeds skepticism. The global tape offers little confirmation. Baxter's themes are company-specific: none of its top keywords appear in the global top-75 for 2026Q4, and the shared ground with other recent reporters is generic — inflationary pressure appears at ODFL and EXE, and warning-letter language at DBVT. The ceph exit, the TSA roll-off and the Novum silence are uniquely Baxter's. The one growth bright spot is also borrowed. Advanced Surgery grew 12%, and Hider conceded why: “There's been a competitor that's had a challenge with supply. And because of our performance and our operation, we've been able to really maximize this impact.” — Andrew Hider, Chief Executive Officer · 2026-10-29 That is good execution, but it is not a durable franchise tailwind. When the competitor recovers, the comp gets harder.

The real question

Baxter is no longer a crisis story. It is a cost-and-cash-flow repair story with a credible operating cadence, a new CFO, and a balance sheet that is nearly repaired. But the Q3 raise was built on better organic growth and cost actions, and it sits alongside a business exit and a deliberately unbuilt 2027 bridge. The stock's next leg depends on whether Rogers can convert the cost actions into a quantified offset for TSA, tariffs, inflation and ceph — or whether the April promise of 'modest growth' becomes the next thing management stops talking about. For now, the tape is giving Baxter the benefit of the doubt on cash. The call did not give it a reason to extend that credit to 2027.